Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment.
The association between malignancy and clinical thrombosis has been recognized for nearly 140 years. The purpose of this review is to examine our current understanding of thrombosis as a complication of cancer and cancer therapy. The review includes a discussion of the epidemiology, pathophysiology, diagnosis and treatment.
Sutherland
Douglas E
DE
Division of Hematology, Department of Medicine, University of Southern California-Keck School of Medicine, Los Angeles, California 90033, USA.
Weitz
Ilene C
IC
Liebman
Howard A
HA
D000465:Algorithms; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers; D002405:Catheterization, Central Venous / Q000009:adverse effects; D003546:Cysteine Endopeptidases / Q000378:metabolism; D003952:Diagnostic Imaging; D004211:Disseminated Intravascular Coagulation; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D008297:Male; D009363:Neoplasm Proteins / Q000378:metabolism; D009369:Neoplasms / Q000097:blood / Q000150:complications*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011183:Postoperative Complications / Q000209:etiology; D013923:Thromboembolism / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control; D019851:Thrombophilia / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D020246:Venous Thrombosis / Q000453:epidemiology / Q000209:etiology
D000925:Anticoagulants; D015415:Biomarkers; D005343:Fibrinolytic Agents; D009363:Neoplasm Proteins; D010975:Platelet Aggregation Inhibitors; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant